Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis have?
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis has 154 citations in the OpenAlex counts ScholarIQ stores.
When was Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis published?
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis has 2018 year in the ScholarIQ index.
What is the open-access status of Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis?
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis has hybrid oa status in the ScholarIQ index.
What is the DOI of Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis?
The DOI for Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis is on the source record.
What is the PMID of Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis?
The PMID for Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis is on the source record.
What is the OpenAlex record for Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis?
The OpenAlex for Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis is on the source record.